Spark Therapeutics (ONCE) Upgraded to “Hold” at ValuEngine

ValuEngine upgraded shares of Spark Therapeutics (NASDAQ:ONCE) from a sell rating to a hold rating in a report published on Wednesday morning.

Several other brokerages have also weighed in on ONCE. Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics and gave the stock a buy rating in a report on Monday, December 11th. Raymond James Financial reissued a buy rating and set a $75.00 price objective on shares of Spark Therapeutics in a report on Thursday, December 7th. Credit Suisse Group reissued an outperform rating and set a $75.00 price objective (up previously from $61.00) on shares of Spark Therapeutics in a report on Thursday, March 8th. Barclays reissued a buy rating and set a $64.00 price objective (up previously from $61.00) on shares of Spark Therapeutics in a report on Tuesday, January 23rd. Finally, SunTrust Banks lifted their price objective on Spark Therapeutics to $113.00 and gave the stock a buy rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and sixteen have issued a buy rating to the company. Spark Therapeutics currently has a consensus rating of Buy and an average price target of $70.58.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ ONCE opened at $66.59 on Wednesday. The company has a market capitalization of $2,478.31, a price-to-earnings ratio of -8.73 and a beta of 2.82. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.73). Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. The company had revenue of $7.41 million for the quarter, compared to analyst estimates of $9.53 million. equities analysts anticipate that Spark Therapeutics will post -3.42 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the stock. Aperio Group LLC boosted its stake in Spark Therapeutics by 29.2% in the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 898 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Spark Therapeutics by 5.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 21,428 shares of the biotechnology company’s stock valued at $1,102,000 after buying an additional 1,013 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in Spark Therapeutics by 47.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock valued at $351,000 after buying an additional 1,264 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in Spark Therapeutics by 15.5% in the 4th quarter. Glenmede Trust Co. NA now owns 10,850 shares of the biotechnology company’s stock valued at $557,000 after buying an additional 1,456 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in Spark Therapeutics by 3.8% in the 3rd quarter. California State Teachers Retirement System now owns 42,716 shares of the biotechnology company’s stock valued at $3,809,000 after buying an additional 1,570 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This story was first published by WKRB News and is owned by of WKRB News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.wkrb13.com/2018/03/31/spark-therapeutics-once-upgraded-to-hold-at-valuengine.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply